MET Mutation Associated with Responsiveness to Crizotinib

J Thorac Oncol. 2015 May;10(5):e29-e31. doi: 10.1097/JTO.0000000000000478.

Authors

Saiama N Waqar¹, Daniel Morgensztern², Jennifer Sehn³

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Washington University, School of Medicine, St. Louis, MO.
² Division of Medical Oncology, Department of Internal Medicine, Washington University, School of Medicine, St. Louis, MO. Electronic address: dmorgens@dom.wustl.edu.
³ Department of Pathology, Washington University, School of Medicine, St. Louis, MO.

No abstract available

Publication types

Case Reports
Letter
Research Support, N.I.H., Extramural

MeSH terms

Adenocarcinoma / genetics
Adenocarcinoma / therapy*
Aged
Antineoplastic Agents / therapeutic use*
Crizotinib
Humans
Lung Neoplasms / genetics
Lung Neoplasms / therapy*
Male
Mutation*
Proto-Oncogene Proteins c-met / genetics*
Pyrazoles / therapeutic use*
Pyridines / therapeutic use*
Retreatment

Substances

Antineoplastic Agents
Pyrazoles
Pyridines
Crizotinib
MET protein, human
Proto-Oncogene Proteins c-met

Grants and funding